Drug intelligence / Profile preview

LSI-205

Development stage: Preclinical
Lead developer: LipoSeuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

LSI-205 is a liposomal reformulation of a generic oncology small molecule drug currently in development by LipoSeuticals. Part of a pipeline of liposomal-encapsulated chemotherapeutics, LSI-205 is designed for intravenous administration to treat various cancers. The specific active pharmaceutical ingredient (API) for LSI-205 has not been publicly disclosed by the developer, though it is categorized within their oncology portfolio alongside other reformulated generics such as irinotecan (LSI-201) and docetaxel (LSI-202). The goal of the LSI-205 program is to leverage liposomal delivery to enhance the efficacy and reduce the toxicity of the underlying small molecule agent by optimizing its pharmacokinetic profile and biodistribution.

Beyond the preview

Go deeper on LSI-205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LSI-205.

Explore the full profile